Search Within

Eileen O'Reilly

Formats
  1. Meeting Abstract (370)
  2. Journal Article (365)
  3. Review (24)
  4. Book Section (9)
  5. Correspondence (9)
  6. Editorial (8)
  7. Conference Paper (5)
  8. Miscellaneous (5)
  9. Book Whole (4)
  10. Guidelines (3)
  11. Research Letter (1)
Groups
  1. Center for Pancreatic Cancer Research (803)
  2. Department of Medicine (803)
  3. Gastrointestinal Oncology Service (803)
  4. Solid Tumor Oncology Division (803)
  5. Epidemiology and Biostatistics (184)
  6. Surgery (173)

More Groups

People
  1. Ghassan Abou-Alfa (160)
  2. Kenneth Yu (123)
  3. David Kelsen (112)
  4. Maeve Lowery (99)
  5. Marinela Capanu (97)
  6. William Jarnagin (88)

More People

Years
  1. 2025 (50)
  2. 2024 (76)
  3. 2023 (73)
  4. 2022 (57)
  5. 2021 (54)
  6. 2020 (70)

More Years

Publications
  1. Journal of Clinical Oncology (296)
  2. Annals of Oncology (51)
  3. Cancer (28)
  4. Annals of Surgical Oncology (26)
  5. Clinical Cancer Research (23)
  6. Gastrointestinal Cancer Research (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (312)
  2. Oxford University Press (75)
  3. Elsevier Inc. (49)
  4. Springer (47)
  5. Wiley Blackwell (43)
  6. American Association for Cancer Research (40)

More Publishers

Results (803)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma
    Meeting Abstract

    Del Rivero, J.; Perez, K.; Geyer, S. M.; Khalil, M. F.; Vijendran, A.; Kordaris-Corkill, A.; Shergill, A.; Spencer, K. R.; Soares, H. P.; Lopez, C. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA 1/2+) pathogenic variants: SWOG S2001
    Meeting Abstract

    Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Reiss, K. A.; Lowy, A. M.; Sohal, D.; Colby, S.; Sharon, E.; Allegra, C. J.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy
    Meeting Abstract

    O'Hara, M. H.; Wattenberg, M. M.; Garrido-Laguna, I.; O'Reilly, E. M.; Yellin, M. J.; Keler, T.; Gargano, M. A.; Niles, N.; Drees, J.; Bose, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer
    Meeting Abstract

    Chawla, A.; Shi, Q.; Ko, A. H.; Beg, S.; Varghese, A. M.; Behrman, S. W.; Bloomston, M.; Ahmed, F. S.; Frankel, W. L.; Dixon, J. G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial
    Meeting Abstract

    Smith, J. J.; Dasari, A.; Shi, Q.; Garcia-Aguilar, J.; Sanoff, H. K.; George, T. J.; Hong, T. S.; Yothers, G.; Philip, P. A.; Nelson, G. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004
    Meeting Abstract

    Yaeger, R.; Shi, Q.; Dueck, A. C.; Dib, E. G.; Kazmi, S. M. A.; Alese, O. B.; Krishnamurthi, S. S.; Nixon, A. B.; Shergill, A.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Park, H.; Geyer, S. M.; Klute, K.; Bleeker, J.; King, D.; Strickland, M.; Goodrich, A.; Carlisle, D.; Shergill, A.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors
    Meeting Abstract

    Bodei, L.; Kavan, P.; Liberman, M.; Taunk, N.; Metser, U.; Juneau, D.; O'Reilly, E. M.; Ma, J.; Cioci, R.; Abdul Razak, A. R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with Lynch syndrome (LS)
    Meeting Abstract

    Harrold, E.; Vanderbilt, C.; Maio, A.; Borio, M.; Ranganathan, M.; Sheehan, M.; O'Connor, C.; Murciano-Goroff, Y. R.; Walsh, M. F.; Will, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC)
    Meeting Abstract

    Keane, F.; Saadat, L.; O'Connor, C.; Chou, J. F.; Brannon, A. R.; Cowzer, D.; Crowley, F.; Debnath, N.; Bowman, A.; Xu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save